Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance

BioNTech SE - ADRTrade
YieldMax TSLA Option Income Strategy ETFTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs YieldMax TSLA Option Income Strategy ETF — how do they compare? BioNTech SE - ADR trades at $93.14 (market cap $23.31B), while YieldMax TSLA Option Income Strategy ETF trades at $21.47. The key difference: BioNTech SE - ADR is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.

BNTXTSLY
Market Cap
$23.31B
Sector
HealthIncome / Options Overlay
52-Week High
$119.34$48.25
52-Week Low
$83.89$20.49
Enterprise Value
$6.60B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.

The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.

YieldMax TSLA Option Income Strategy ETF

TSLY trades at $21.51, down 1.01% today, with a bearish technical signal from moving averages and mixed oscillators. The ETF generates high income through weekly distributions, but faces capped upside due to its covered call strategy on Tesla. Recent news highlights concerns over missed Tesla rallies and reduced upside capture, while distributions remain consistent, averaging around $0.28 per share recently.

Outlook is cautious due to structural limitations in capturing Tesla's gains, presenting income opportunity but significant growth risk. Investors face volatility from Tesla's performance and potential return of capital in distributions, warranting careful assessment of income versus capital appreciation goals.

Returns comparison

Trailing returns across standard periods

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About YieldMax TSLA Option Income Strategy ETF

TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.

Read more on TSLY